Drugs that contain Doravirine
1. List of Pifeltro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 30, 2023 |
| New Indication (I) | Sep 19, 2022 |
| New Patient Population (NPP) | Jan 27, 2025 |
NCE-1 date: August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; For use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic